These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 25153718)
1. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Datta A; Loo SY; Huang B; Wong L; Tan SS; Tan TZ; Lee SC; Thiery JP; Lim YC; Yong WP; Lam Y; Kumar AP; Yap CT Oncotarget; 2014 Aug; 5(15):5920-33. PubMed ID: 25153718 [TBL] [Abstract][Full Text] [Related]
2. Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis. Wang S; Liang Y; Chang W; Hu B; Zhang Y Med Sci Monit; 2018 Apr; 24():1912-1923. PubMed ID: 29605826 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110 [TBL] [Abstract][Full Text] [Related]
4. Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. Acharya S; Yao J; Li P; Zhang C; Lowery FJ; Zhang Q; Guo H; Qu J; Yang F; Wistuba II; Piwnica-Worms H; Sahin AA; Yu D Cancer Res; 2019 Aug; 79(16):4211-4226. PubMed ID: 31239273 [TBL] [Abstract][Full Text] [Related]
5. Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival. Maiti A; Takabe K; Hait NC Cell Signal; 2017 Apr; 32():85-92. PubMed ID: 28108260 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of SphK1 enhances cell proliferation and invasion in triple-negative breast cancer via the PI3K/AKT signaling pathway. Li J; Song Z; Wang Y; Yin Y; Liu Y; Yuan R; Nan X Tumour Biol; 2016 Aug; 37(8):10587-93. PubMed ID: 26857281 [TBL] [Abstract][Full Text] [Related]
7. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells. Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795 [TBL] [Abstract][Full Text] [Related]
8. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer. Black JL; Harrell JC; Leisner TM; Fellmeth MJ; George SD; Reinhold D; Baker NM; Jones CD; Der CJ; Perou CM; Parise LV Breast Cancer Res Treat; 2015 Jul; 152(2):337-46. PubMed ID: 26105795 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade. Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177 [TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors. Clark NC; Friel AM; Pru CA; Zhang L; Shioda T; Rueda BR; Peluso JJ; Pru JK Cancer Biol Ther; 2016; 17(3):262-71. PubMed ID: 26785864 [TBL] [Abstract][Full Text] [Related]
11. Role of Sphk1 in the malignant transformation of breast epithelial cells and breast cancer progression. Zheng XD; Zhang Y; Qi XW; Wang MH; Sun P; Zhang Y; Jiang J Indian J Cancer; 2014; 51(4):524-9. PubMed ID: 26842184 [TBL] [Abstract][Full Text] [Related]
12. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. Dayon A; Brizuela L; Martin C; Mazerolles C; Pirot N; Doumerc N; Nogueira L; Golzio M; Teissié J; Serre G; Rischmann P; Malavaud B; Cuvillier O PLoS One; 2009 Nov; 4(11):e8048. PubMed ID: 19956567 [TBL] [Abstract][Full Text] [Related]
13. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro. Yao C; Wu S; Li D; Ding H; Wang Z; Yang Y; Yan S; Gu Z Mol Oncol; 2012 Aug; 6(4):392-404. PubMed ID: 22583777 [TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer. Ochnik AM; Baxter RC BMC Cancer; 2017 Dec; 17(1):820. PubMed ID: 29207959 [TBL] [Abstract][Full Text] [Related]
15. Sphingosine Kinase 1 Regulates the Survival of Breast Cancer Stem Cells and Non-stem Breast Cancer Cells by Suppression of STAT1. Hii LW; Chung FF; Mai CW; Yee ZY; Chan HH; Raja VJ; Dephoure NE; Pyne NJ; Pyne S; Leong CO Cells; 2020 Apr; 9(4):. PubMed ID: 32260399 [TBL] [Abstract][Full Text] [Related]
16. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer. Ring A; Kaur P; Lang JE BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of ERK5 targeting in triple negative breast cancer. Ortiz-Ruiz MJ; Álvarez-Fernández S; Parrott T; Zaknoen S; Burrows FJ; Ocaña A; Pandiella A; Esparís-Ogando A Oncotarget; 2014 Nov; 5(22):11308-18. PubMed ID: 25350956 [TBL] [Abstract][Full Text] [Related]
18. Divergence of Intracellular Trafficking of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Receptor 3 in MCF-7 Breast Cancer Cells and MCF-7-Derived Stem Cell-Enriched Mammospheres. Sukocheva OA; Hu DG; Meech R; Bishayee A Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919234 [TBL] [Abstract][Full Text] [Related]
19. Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells. Bassey-Archibong BI; Rayner LG; Hercules SM; Aarts CW; Dvorkin-Gheva A; Bramson JL; Hassell JA; Daniel JM Cell Death Dis; 2017 Mar; 8(3):e2689. PubMed ID: 28333150 [TBL] [Abstract][Full Text] [Related]
20. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]